SI3386507T1 - Postopki in sestavki za zdravljenje gastričnih razjed - Google Patents

Postopki in sestavki za zdravljenje gastričnih razjed

Info

Publication number
SI3386507T1
SI3386507T1 SI201631743T SI201631743T SI3386507T1 SI 3386507 T1 SI3386507 T1 SI 3386507T1 SI 201631743 T SI201631743 T SI 201631743T SI 201631743 T SI201631743 T SI 201631743T SI 3386507 T1 SI3386507 T1 SI 3386507T1
Authority
SI
Slovenia
Prior art keywords
compositions
methods
gastric ulcers
treating gastric
treating
Prior art date
Application number
SI201631743T
Other languages
English (en)
Inventor
Nicholas Bova
Sanjay Garg
Stephen Page
Original Assignee
Luoda Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905078A external-priority patent/AU2015905078A0/en
Application filed by Luoda Pharma Limited filed Critical Luoda Pharma Limited
Publication of SI3386507T1 publication Critical patent/SI3386507T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201631743T 2015-12-08 2016-12-08 Postopki in sestavki za zdravljenje gastričnih razjed SI3386507T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905078A AU2015905078A0 (en) 2015-12-08 Methods and Compositions For Treating Gastric Ulcers
EP16871822.9A EP3386507B1 (en) 2015-12-08 2016-12-08 Methods and compositions for treating gastric ulcers
PCT/AU2016/051205 WO2017096426A1 (en) 2015-12-08 2016-12-08 Methods and compositions for treating gastric ulcers

Publications (1)

Publication Number Publication Date
SI3386507T1 true SI3386507T1 (sl) 2023-10-30

Family

ID=59012417

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631743T SI3386507T1 (sl) 2015-12-08 2016-12-08 Postopki in sestavki za zdravljenje gastričnih razjed

Country Status (17)

Country Link
US (2) US11318123B2 (sl)
EP (1) EP3386507B1 (sl)
AU (1) AU2016367707B2 (sl)
BR (1) BR112018011552A2 (sl)
CA (1) CA3007446C (sl)
DK (1) DK3386507T3 (sl)
ES (1) ES2953929T3 (sl)
FI (1) FI3386507T3 (sl)
HK (1) HK1254232A1 (sl)
HR (1) HRP20231051T1 (sl)
HU (1) HUE062857T2 (sl)
MX (1) MX2018006921A (sl)
PL (1) PL3386507T3 (sl)
PT (1) PT3386507T (sl)
SI (1) SI3386507T1 (sl)
WO (1) WO2017096426A1 (sl)
ZA (1) ZA201804478B (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364371A (zh) * 2019-07-16 2022-04-15 金德雷德生物科学股份有限公司 马科动物埃索美拉唑配制品及其用途
KR102289089B1 (ko) 2019-12-24 2021-08-11 동아대학교 산학협력단 인후두 역류질환 치료 또는 예방용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512771A (en) 1999-02-23 2003-02-28 Merck & Co Inc Pharmaceutical composition containing omeprazole in a hydrophobic oily liquid vechicle
WO2004103291A2 (en) 2003-05-16 2004-12-02 Eisai Co., Ltd. Extended release compositions of proton pump inhibitor
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
FR2879930B1 (fr) * 2004-12-23 2007-08-31 Oralance Pharma Sa Nouveau systeme galenique pour le transport d'actif, procede de preparation et utilisation
CN1813729A (zh) * 2005-02-02 2006-08-09 兰贝克赛实验室有限公司 苯并咪唑化合物的注射制剂
US20090214599A1 (en) 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations
DE102009018133A1 (de) 2009-04-15 2010-11-11 Agon Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
CN103127006B (zh) * 2013-03-08 2014-08-06 苏州特瑞药业有限公司 一种注射用右旋兰索拉唑组合物及其制备方法
CN103222962B (zh) * 2013-05-10 2014-12-24 苏州特瑞药业有限公司 一种注射用埃索美拉唑组合物及其制备方法
CN103239448A (zh) 2013-05-20 2013-08-14 青岛正大海尔制药有限公司 一种注射用埃索美拉唑钠冻干粉组合物及其制备方法
CN103637986B (zh) * 2013-12-12 2016-04-06 挑战(天津)动物药业有限公司 一种奥美拉唑纳米乳液及其制备方法

Also Published As

Publication number Publication date
HRP20231051T1 (hr) 2023-12-22
ZA201804478B (en) 2020-12-23
CA3007446A1 (en) 2017-06-15
US20180133201A1 (en) 2018-05-17
ES2953929T3 (es) 2023-11-17
FI3386507T3 (fi) 2023-09-06
AU2016367707B2 (en) 2022-01-27
NZ743099A (en) 2023-12-22
WO2017096426A1 (en) 2017-06-15
CA3007446C (en) 2024-01-16
DK3386507T3 (da) 2023-09-18
EP3386507A1 (en) 2018-10-17
PL3386507T3 (pl) 2023-10-23
HUE062857T2 (hu) 2023-12-28
EP3386507B1 (en) 2023-06-07
BR112018011552A2 (pt) 2018-11-27
AU2016367707A1 (en) 2018-06-21
HK1254232A1 (zh) 2019-07-12
PT3386507T (pt) 2023-09-11
US11318123B2 (en) 2022-05-03
US20220202797A1 (en) 2022-06-30
MX2018006921A (es) 2019-05-16
EP3386507A4 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
IL304820A (en) Preparations and methods for the treatment of cancer
PT3377516T (pt) Composição para o tratamento do cancro
GB2558326B (en) Methods and compositions for inhibiting and treating neurological conditions
HK1254432A1 (zh) 用於治療纖維性疾病的方法和組合物
EP3209298A4 (en) Compositions and methods for treating insomnia
RS61929B1 (sr) Postupci i sastavi za tretman raka
HUE054204T2 (hu) Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
IL256523A (en) Compositions and methods for treating cancer
EP3154544A4 (en) Compositions and methods for treating cancers
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
EP3220908A4 (en) Compositions and methods for treating endometriosis
IL255638A (en) Compositions and methods for treating cancer
HK1254232A1 (zh) 用於治療胃潰瘍的方法和組合物
ZA201802268B (en) Methods and compositions for preventing or treating cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
IL257407A (en) Compositions and methods for treating wounds
EP3242664A4 (en) Compositions and methods for treating gastrointestinal infections
AU2015905078A0 (en) Methods and Compositions For Treating Gastric Ulcers
AU2015905079A0 (en) Methods and Compositions for Treating Gastric Ulcers with Esomeprazole
AU2016905099A0 (en) Methods and Compositions For Treating Gastric Ulcers with Esomeprazole
GB201521083D0 (en) Compositions for treatment and methods thereof
HUP1400231A2 (en) Method and composition for treating hard-to-heal ulcer wounds